KLOW Peptide Results in the Research Literature
In plain English — how to read these results
KLOW results in the research literature are, strictly speaking, the results for each of the four individual components studied separately — not results for the KLOW blend, which has never been tested. This page organizes those single-component results by outcome category and by component so the evidence behind each claim is visible.
The blend-level result is an absence: zero controlled studies, zero clinical trials, no pharmacokinetic data for the combination. That absence is a finding in itself — it is the clearest single thing the research record establishes about KLOW as a combination.
Tissue repair and wound healing results
BPC-157 in the Achilles tendon study (Staresinic et al., 2003): intraperitoneal BPC-157 at doses of 10 microg, 10 ng, and 10 pg per rat per day accelerated healing of a fully transected rat Achilles tendon across biomechanical load-to-failure, functional, microscopic, and macroscopic measures; in vitro it stimulated tendocyte (tendon fibroblast) outgrowth [4]. This is one of the most reproducible findings in the BPC-157 rodent literature.
Thymosin beta-4 in the wound model (Malinda et al., 1999): topical or intraperitoneal full-length Tbeta4 in a rat full-thickness wound model increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, increased wound contraction by at least 11% by day 7, and raised collagen deposition and angiogenesis. As little as 10 pg stimulated keratinocyte (skin-surface cell) migration 2-3-fold in vitro [6]. These results are for the native full-length protein; the TB-500 fragment (Ac-LKKTETQ) has not been validated in comparable wound models.
Thymosin beta-4 exosome hydrogel (Zhang et al., 2025): a Tbeta4-loaded hemostatic and antibacterial hydrogel enhanced vascularized wound repair in a 2025 materials-biology study [15] — a recent exploration of delivery mechanisms for full-length Tbeta4, not for the TB-500 fragment.
Pro-resolving pathway mechanism (Sosne et al., 2024): Tbeta4's therapeutic effects are mediated in part via specialized pro-resolving lipid mediators [14], helping explain anti-inflammatory results beyond the G-actin sequestration mechanism.
Anti-inflammatory and mucosal results
KPV in the intestinal inflammation study (Dalmasso et al., 2008): nanomolar KPV inhibited NF-kappaB nuclear import and MAPK ERK/p38 signaling in human intestinal epithelial cell lines and Jurkat T cells, reducing TNF-alpha, IL-6, IL-1beta, and IL-8 secretion [1]. In C57BL/6 mice with DSS- and TNBS-induced colitis, oral KPV in drinking water reduced colitis severity. The PepT1 transporter mechanism (Km ~160 micromolar) means KPV is preferentially taken up by inflamed epithelium, which upregulates PepT1 — a tissue-selective delivery advantage.
BPC-157 NSAID-toxicity results (Ilic et al., 2011): BPC-157 counteracted diclofenac-induced GI, liver, and encephalopathy lesions in a rat NSAID-toxicity model [9]. A 2013 review by Sikiric et al. consolidated rodent evidence for BPC-157's mitigation of NSAID-induced organ toxicity across multiple systems [10]. A 2025 review updated the safety and counter-intoxication framing [13].
Matrix synthesis and gene expression results
GHK-Cu transcriptomics (Pickart and Margolina, 2018): at a 50%-or-greater change threshold, GHK-Cu modulates approximately 31.2% of human genes in the published Connectivity Map analysis — increasing expression of 59% of affected genes and suppressing 41%, with the strongest signals on the ubiquitin-proteasome system (41 genes up, 1 down), DNA-repair gene sets, and antioxidant programs [2].
GHK-Cu skin regeneration review (Pickart et al., 2015): GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin; plasma GHK levels decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [3]. In placebo-controlled topical work, GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid, with documented improvements in skin laxity, fine lines, and wrinkle depth.
Human clinical results
BPC-157 IV safety pilot (Lee and Burgess, 2025): the single human study for any KLOW component via systemic administration. Intravenous BPC-157 at 10 mg on day 1 and 20 mg on day 2 by 1-hour infusion in two healthy adults was well tolerated with no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers [5]. n=2; not an efficacy study.
Thymosin beta-4 dry-eye RCT (Sosne et al., 2015): in a randomized, placebo-controlled Phase II trial, topical thymosin beta-4 ophthalmic solution (RGN-259) improved signs and symptoms of dry eye [11]. The ARISE-3 trial (NCT03937882) completed further assessment in 2020 [12]. These results are for topical full-length Tbeta4 ophthalmic application — a narrow indication far from the systemic tissue-repair use case for which TB-500 is discussed in research communities.
GHK-Cu topical cosmetic: the most extensive human record among the four components, but all topical and all focused on skin — not systemic musculoskeletal or anti-inflammatory endpoints.
The blend-level result: none
No controlled study has tested the KPV + GHK-Cu + BPC-157 + TB-500 combination. Zero randomized trials, zero animal-model combination studies, zero pharmacokinetic combination studies. A 2026 Sports Medicine systematic review of unapproved peptide therapies — specifically covering TB-500 and BPC-157 — concluded favorable animal-model outcomes but scarce human safety data and no regulatory approval [7].
The pharmacokinetic mismatch within the blend (see the dosage page) means that even a well-designed combination study would need to address the fundamentally different clearance rates of the four components before interpreting any combination outcome.